News in the Life Sciences Industry

Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin(®) clinical trial.

STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the last patient has been successfully enrolled in the pivotal phase 3 study OCEAN in relapsed refractory multiple myeloma (RRMM). The original enrollment target of 450 patients was reached... Read more ››

STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- Q-linea AB (publ) (OMX: QLINEA), today announced that an ASTar® instrument is now being used for beta testing at Uppsala University Hospital and that the hospital will participate in the company's European pivotal clinical study.

LINKÖPING, Sweden, Sept. 4, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO:... Read more ››

LUND, Sweden, Sept. 4, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic... Read more ››

STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today September 4(th) 2020, that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing Professor Georg Holländer, Action Research Professor and Head of Department... Read more ››

STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today September 4(th) 2020, that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing Professor Georg Hollaender, Action Research Professor and Head of Department... Read more ››

OSLO, Norway, Sept. 3, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces the publication in Blood Advances, an official journal of the American Society of Hematology, of the mature data from the LYMRIT 37-01 - Part A trial (A. Kolstad et al. - ref. below).

STOCKHOLM, Sept. 3, 2020 /PRNewswire/ -- "We are proud to bring our SyMRI software to the Japanese market" says Ulrik Harrysson, CEO, SyntheticMR. "We have an established customer base in Japan currently using the product for research. Now we are excited to be able to offer SyMRI for clinical... Read more ››